Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ACSL3 antisense RNA 1 (ACSL3-AS1) is a long noncoding RNA gene transcript located antisense to the ACSL3 protein-coding gene[1]. Unlike ACSL3, an enzyme that activates fatty acids and is implicated in cancer progression and metabolism[2][3][4], ACSL3-AS1’s function is poorly characterized and is not recognized as a classical therapeutic target. There is no direct evidence of drugs or clinical interventions targeting ACSL3-AS1. Its presence may be relevant in gene regulatory studies, but its clinical significance remains underexplored[1]. Do not conflate ACSL3-AS1 with ACSL3: ACSL3 is a validated therapeutic target related to enzymes and cancer biology[2][3][4], whereas ACSL3-AS1 is a noncoding RNA with unknown or unproven direct roles in disease or therapy[1].
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ACSL3 antisense RNA 1 (ACSL3-AS1).